Skip to main content
    C

    China SXT Pharmaceuticals Inc (SXTC)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $2.99
    -0.01 (-0.33%)

    Market Cap: $310,720

    Last updated: Nov 17, 2026 at 11:05 AM ET

    China SXT Pharmaceuticals Inc (SXTC) Financials: Revenue, Profit and Cash Flow

    Updated Jul 1, 2026. Financial statements from company filings, amounts in US dollars.

    China SXT Pharmaceuticals reported revenue of $1.07M for the fiscal year ended Mar 31, 2026, down 38.4% from the year before. That year, net income was -$6.21M with a net margin of -578.5%, operating cash flow was -$4.02M and free cash flow was -$4.02M. The quarter ended Jun 30, 2026 had revenue of $1.20M and net income of $163.72K.

    Revenue and Margins

    Over the 9 years to Mar 2026, revenue fell from $4.88M, a compound annual decline of 15.5%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Mar 2026$1.07M-38.4%17.1%-664.1%-578.5%
    Mar 2025$1.74M-9.7%21.1%-154.0%-189.8%
    Mar 2024$1.93M-2.2%28.7%-130.4%-160.7%
    Mar 2023$1.97M-24.2%21.6%-284.4%-301.0%
    Mar 2022$2.60M-45.5%48.1%-199.4%-220.4%
    Mar 2021$4.78M-7.5%59.4%-46.0%-57.5%
    Mar 2020$5.16M-26.4%52.4%-26.0%-199.3%
    Mar 2019$7.01M-0.1%65.8%25.2%22.0%
    Mar 2018$7.02M+43.8%48.5%23.3%16.9%
    Mar 2017$4.88MN/A47.4%32.8%24.3%
    Annual, fiscal years ended Mar 2017 to Mar 2026

    Income Statement

    In the fiscal year ended Mar 2026, the net loss widened from the year before. In the quarter ended Jun 2026, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Revenue$1.07M$1.74M$1.93M$1.97M$2.60M$4.78M$5.16M$7.01M$7.02M$4.88M
    Cost of revenue$889.35K$1.37M$1.37M$1.55M$1.35M$1.94M$2.46M$2.40M$3.62M$2.57M
    Gross profit$183.28K$367.43K$553.97K$426.27K$1.25M$2.84M$2.70M$4.61M$3.40M$2.31M
    Research and development$178.76K$191.39K$184.19K$0$0$0$0$0$0$0
    Operating income-$7.12M-$2.68M-$2.52M-$5.61M-$5.19M-$2.20M-$1.34M$1.77M$1.63M$1.60M
    Net income-$6.21M-$3.30M-$3.10M-$5.93M-$5.74M-$2.75M-$10.29M$1.54M$1.19M$1.19M
    EBITDA-$6.98M-$2.57M-$2.35M-$5.21M-$5.05M-$1.85M-$1.01M$1.98M$1.76M$1.70M
    Fiscal years ended Mar 2017 to Mar 2026

    Quarterly

    Line itemJun 2026Dec 2025Sep 2025Jun 2025Dec 2024Jun 2024Dec 2023Sep 2023Jun 2023Dec 2022Sep 2022Jun 2022
    Revenue$1.20M$255.74K$626.57K-$1.01M$455.71K$414.75K$751.07K$898.16K$469.79K$381.70K$1.21M-$11.50M
    Gross profit$833.97K$73.49K$101.72K-$825.90K$116.34K$67.38K$389.43K$144.17K$144.17K$168.29K$89.68K-$15.53M
    Operating income-$784.01K-$392.00K-$6.34M-$3.17M-$1.02M-$319.13K$3.42M-$4.67M-$4.67M-$2.23M-$1.15M$1.28M
    Net income$163.72K$81.86K-$6.37M-$81.86K-$1.25M-$401.28K$3.30M-$4.85M-$4.85M-$2.22M-$1.49M$2.32M
    Last 12 quarters

    Balance Sheet

    As of Mar 2026, cash and equivalents exceeded total debt of $1.07M by $27.11M.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Total assets$34.75M$21.66M$23.13M$29.55M$33.55M$34.55M$21.70M$17.47M$7.66M$5.43M
    Current assets$34.51M$21.30M$14.23M$19.52M$22.45M$23.23M$19.64M$15.59M$6.10M$4.91M
    Cash and equivalents$28.18M$18.10M$12.07M$17.37M$15.52M$13.33M$7.29M$9.13M$560.25K$65.57K
    Total liabilities$5.05M$6.22M$9.20M$14.86M$17.12M$18.59M$12.30M$6.36M$4.37M$3.58M
    Short-term debt$423.15K$772.19K$2.35M$3.39M$10.74M$37.12K$6.69M$2.74M$385.12K$302.17K
    Long-term debt$644.39K$96.26K$117.13K$117.86KN/A$6.29K$36.51KN/AN/AN/A
    Shareholder equity$29.71M$15.44M$13.93M$14.69M$16.42M$15.96M$9.40M$11.11M$3.29M$1.85M
    Fiscal years ended Mar 2017 to Mar 2026

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$34.75M$34.75M$34.75M$26.35M$26.35M$21.66M$21.66M$29.99M$31.00M$23.13M$23.13M$14.59M
    Total liabilities$5.05M$5.05M$5.05M$6.12M$6.12M$6.22M$6.22M$19.81M$15.96M$9.20M$9.20M$9.52M
    Cash and equivalents$28.18M$28.18M$28.18M$21.17M$21.17M$18.10M$18.10MN/A$18.51M$12.07M$12.07M$11.47M
    Shareholder equity$29.71M$29.71M$29.71M$20.23M$20.23M$15.44M$15.44M$10.18M$15.03M$13.93M$13.93M$5.08M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Mar 2026.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Operating cash flow-$4.02M-$2.35M-$1.93M-$80.76K-$2.37M-$1.32M$934.25K$239.19K$1.92M$293.04K
    Capital expenditures$4$2.02K$7.06K$70.68K$62.49K$93.04K$406.66K$610.09K$1.05M$186.31K
    Free cash flow-$4.02M-$2.35M-$1.94M-$151.44K-$2.44M-$1.41M$527.59K-$370.89K$869.44K$106.73K
    Dividends paidN/AN/AN/AN/AN/AN/AN/A$2.38MN/AN/A
    Investing cash flow-$1.25M$63.52K$26.42K-$12.30K-$46.91K-$5.81M-$5.50M-$610.09K-$1.14M-$186.31K
    Financing cash flow$14.43M$8.40M-$2.62M$2.94M$1.63M$12.41M$3.02M$9.04M-$314.22K-$50.56K
    Fiscal years ended Mar 2017 to Mar 2026

    Quarterly

    Line itemJun 2026Dec 2025Sep 2025Jun 2025Dec 2024Jun 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Operating cash flow-$2.26M-$1.13M-$1.75M-$876.28K-$719.89K-$664.79K-$674.24K-$141.63K-$289.78KN/A$234.18K
    Capital expenditures$0$0$4$988.15K$1.01K$3.53K$3.53K$0$50.57K$0$25.28K
    Free cash flow-$2.26M-$1.13M-$1.75M-$1.86M-$720.90K-$668.33K-$677.77K-$141.63K-$340.35KN/A$208.90K
    Last 11 quarters

    Frequently Asked Questions About SXTC

    What is China SXT Pharmaceuticals' annual revenue?

    China SXT Pharmaceuticals reported revenue of $1.07M for the fiscal year ended Mar 31, 2026.

    How fast is China SXT Pharmaceuticals' revenue growing?

    Revenue was down 38.4% for the fiscal year ended Mar 31, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was -18.4%.

    Is China SXT Pharmaceuticals profitable?

    No. China SXT Pharmaceuticals reported net income of -$6.21M for the fiscal year ended Mar 31, 2026, with a net margin of -578.5%.

    How much free cash flow does SXTC generate?

    For the fiscal year ended Mar 31, 2026, operating cash flow of -$4.02M minus capital expenditures of $4 produced free cash flow of -$4.02M.

    How much debt does China SXT Pharmaceuticals have?

    The balance sheet dated Mar 31, 2026 reported long-term debt of $644.39K, short-term debt of $423.15K and cash and equivalents of $28.18M.